Skip to content
Search

Latest Stories

NHS to start world’s first 'artificial pancreas' trial, 100 years after discovery of insulin

Around 1,000 NHS patients with type 1 diabetes will take part in a trial of systems that continually monitor blood sugar levels and automatically adjust the amount of insulin given via a pump, according to a report in The Times.

Made by Medtronic, the device is the first hybrid closed-loop insulin delivery system to be approved anywhere in the world.


The pilot scheme will submit data to a national audit. Those results will feed into an assessment by the National Institute for Health and Care Excellence, which is considering whether NHS adoption of the technology would be “a clinically and cost-effective use of NHS resources”, the report said.

Patients taking part in the trial are expected to be those already using an insulin pump and wearing glucose monitors, but struggling to keep their blood sugar levels under control.

Experts hope that the new technology can prevent life-threatening hypoglycaemic attacks, as well as making patients’ lives easier by eliminating the need for finger prick tests, the report added.

“Living with diabetes is a daily challenge for millions of people, and this closed-loop technology has the potential to make a remarkable difference to their lives,” Sir Simon Stevens, chief executive of NHS England, told The Times.

“In a year that marks a century since insulin was discovered — which revolutionised the world of diabetes — this innovation is a prime example of the NHS’s continued progress in modern medicine and technology.”

People with type 1 diabetes — 8 per cent of people with diabetes in the UK — cannot produce enough insulin. They need daily doses of the hormone to keep blood sugar levels under control, delivered via an injector pen or a pump. Before the discovery of insulin in 1921 people with type 1 diabetes rarely lived more than a year or two.

Patients have traditionally taken regular blood sugar readings by pricking their fingers, although two fifths now use devices such as the Freestyle Libre, worn under the skin to monitor glucose levels.

They then inject insulin as needed. The new artificial pancreas goes further, with readings sent to a smart device that calculates how much insulin is needed and tells an insulin pump worn by the patient how much to release.

“One hundred years after the discovery of insulin, the artificial pancreas is a potentially revolutionary development in the treatment of diabetes,” Professor Partha Kar, the NHS national speciality adviser for diabetes, told The Times.

“The NHS has long been at the forefront of clinical advances in care for major diseases, including diabetes, which have allowed patients to live longer and healthier lives.”

More For You

Hay fever treatment: Dymista nasal spray now available in pharmacies without prescription

Hay fever affects one in four people in the UK

gettyimages

Hay fever treatment: First OTC combination nasal spray launched

For the first time, a double-action combination treatment for moderate to severe hay fever has been available over the counter across UK pharmacies, offering a new option for those sufferers who remain uncontrolled on a corticosteroid or antihistamine nasal spray.

Launched by global healthcare company Viatris, Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray— previously only available via prescription under the brand name Dymista — can be accessed without a GP visit.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less